Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

January 26, 2022

Study Completion Date

January 26, 2022

Conditions
GoutChronic Kidney Diseases
Interventions
DRUG

Anakinra 100mg and Placebo Depo-Medrone

Anakinra 100mg injection S/C Day 1 to Day 5 and Placebo Depo-Medrone (Lipofundin 3mL) I/M Day 1. Anakinra is an interleukin-1 receptor antagonist. Placebo for Depo-Medrone placebo is Lipofundin MCT/LCT 10%.

DRUG

Depo-Medrone 120mg and Placebo (Anakinra)

Depo-Medrone 120mg in 3mL. Placebo for Anakinra supplied from manufacturer. 120mg Depo-Medrone I/M Day 1 and Placebo Anakinra 100mg injection S/C Day 1 to Day 5.

Trial Locations (1)

SS0 0RY

Southend Hospital, Southend-on-Sea

All Listed Sponsors
collaborator

Anglia Ruskin University

OTHER

collaborator

University of East Anglia

OTHER

collaborator

University of Essex

OTHER

collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

Mid and South Essex NHS Foundation Trust

OTHER

NCT02578394 - Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study | Biotech Hunter | Biotech Hunter